Standard and new treatments in cutaneous B‐cell lymphomas

Dréno, Brigitte

doi:10.1111/j.0303-6987.2006.00544.x

Cited by 30 publications

(28 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…44 However, the efficacy of antibiotic treatment in B burgdorferi-associated PCMZL is poorly documented. 29,31,[45][46][47][48] Six of 14 (43%) reported patients achieved CR after various antibiotic regimens.…”

Section: Antibioticsmentioning

confidence: 99%

See 1 more Smart Citation

European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas

Senff¹,

Noordijk

Kim³

et al. 2008

Blood

406

405

View full text Add to dashboard Cite

Section: Antibioticsmentioning

confidence: 99%

“…1,44 However, only 32 patients receiving CHOP(-like) (n ϭ 29) or COP (n ϭ 3) have been reported. 29,30,40,45,56,80,81,93 Collectively, 26 of 32 patients (81%) reached a CR and 14 of 26 CR patients (54%) had a relapse.…”

Section: Multiagent Chemotherapymentioning

confidence: 99%

European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas

Senff¹,

Noordijk

Kim³

et al. 2008

Blood

406

405

View full text Add to dashboard Cite

“…As for PCFCL, single-agent rituximab may be utilized in patients with symptomatic, widespread skin lesions. An initial trial of antibiotics for those with B. burgdorferi-associated PCMZL has been recommended [30], but is less relevant for North American patients.…”

Section: Pcmzlmentioning

confidence: 99%

Cutaneous B‐cell lymphomas: 2016 update on diagnosis, risk‐stratification, and management

Wilcox

2016

American J Hematol

View full text Add to dashboard Cite

Disease overviewApproximately one‐fourth of cutaneous lymphomas are B‐cell derived and are generally classified into three distinct subgroups: primary cutaneous follicle center lymphoma (PCFCL), primary cutaneous marginal zone lymphoma (PCMZL), and primary cutaneous diffuse large B‐cell lymphoma, leg type (PCDLBCL, LT).DiagnosisDiagnosis and disease classification is based on histologic review and immunohistochemical staining of an appropriate skin biopsy. Pathologic review and an appropriate staging evaluation are necessary to distinguish primary cutaneous B‐cell lymphomas from systemic B‐cell lymphomas with secondary skin involvement.Risk‐stratificationDisease histology remains the most important prognostic determinant. Both PCFCL and PCMZL are indolent lymphomas that infrequently disseminate to extracutaneous sites and are associated with 5‐year survival rates that exceed 95%. In contrast, PCDLBCL, LT is an aggressive lymphoma with an inferior prognosis.Risk‐adapted therapyPCFCL and PCMZL patients with solitary or relatively few skin lesions may be affectively managed with local radiation therapy. While single‐agent rituximab may be employed for patients with more widespread skin involvement, multiagent chemotherapy is rarely appropriate. In contrast, management of patients with PCDLBCL, LT is comparable to the management of patients with systemic DLBCL. Am. J. Hematol. 91:1052–1055, 2016. © 2016 Wiley Periodicals, Inc.

show abstract

“…Regimens typically include an anti-CD20 antibody (rituximab) in comination with the antracycline based chemotherapy regimen CHOP (r-CHOP) [15,17,18]. Radiotherapy may also be considered particularly in presentations of a solitary small skin tumour.…”

Section: Discussionmentioning

confidence: 99%

Primary Cutaneous Diffuse Large B-Cell Lymphoma (Leg Type) Presenting as Necrotising Fasciitis

McInerney¹,

Power²,

Hussey³

2012

MPS

View full text Add to dashboard Cite

Necrotising fasciitis is a rare rapidly progressive, life threatening, soft tissue infection which spreads along fascial planes. We present a patient who was diagnosed with a primary cutaneous Diffuse Large B-Cell Lymphoma (leg type) following initial presentation as probable necrotising fasciitis. Presentation was of a painful swollen leg, septic shock and MRI findings consistent with the clinical signs. Diagnosis of necrotising fasciitis remains challenging and it is often missed in the early stages. Early fascial biopsy and histopathological analysis is useful in cases where the diagnosis is unclear. We feel that this case highlights these important issues and will benefit others in their management of similar cases in the future.

show abstract

Standard and new treatments in cutaneous B‐cell lymphomas

Abstract: In the majority of cases, the treatment of CBCL is straightforward. In aggressive forms, new therapies and biologic therapies may be of real interest.

Cited by 30 publications

References 29 publications

European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas

European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas

Cutaneous B‐cell lymphomas: 2016 update on diagnosis, risk‐stratification, and management

Primary Cutaneous Diffuse Large B-Cell Lymphoma (Leg Type) Presenting as Necrotising Fasciitis

Contact Info

Product

Resources

About